Grant Number:	5U2CCA252981-05 Interpret this number
Primary Investigator:	Colditz, Graham
Organization:	Washington University
Project Title:	Washington University Participant Engagement and Cancer Genomic Sequencing Center (Wu-Pe-Cgs)
Fiscal Year:	2025

Participant engagement and genomic sequencing research from the Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) will fill critical gaps in knowledge, methodology, and characterization of cancer populations requiring more research, leading to optimal approaches for participant engagement, outreach, and communication in genomic characterization studies. Our overall goal is to build a rigorous, scientific evidence base for approaches on direct engagement of patients and post-treatment cancer survivors as research participants. Our focus is on rare cancers in populations with significant adverse outcomes (cholangiocarcinoma, multiple myeloma, and colorectal cancer). Our Center will be housed in an environment that fosters multidisciplinary collaboration, catalyzes new ideas, and ensures support that finds solutions for complex recruitment and engagement challenges. The specific aims are to: (1) Advance the field of participant engagement to study adverse cancer outcomes by conducting innovative and impactful direct stakeholder engagement with continuous evaluation and research; (2) Expand an exceptional, broad team of investigators, patients, and patient interest stakeholders; (3) Address adverse cancer outcomes by understanding challenges and improving the ability for low-resourced populations requiring more research to encounter, use, and benefit from genomic sequencing and analysis; (4) Organize and integrate Center units to facilitate team science within our Center and across the Network. WU-PE-CGS builds on a long, outstanding leadership record in cancer and genomic research across the cancer continuum and will enable a significant return on scientific investment in several ways. First, our Center has distinctive features, including a combined focus on adverse cancer outcomes, application of strategies to increase participant engagement, biospecimen acquisition success, and exceptional genomic sequencing expertise. Second, we have assembled a broad, world-class team with strong links to multiple rare cancers. Third, we engage investigators from different disciplines and invest in developing early career scholars. Fourth, we strategically and creatively disseminate products in ways that benefit researchers, practitioners, and community members. Fifth, we will partner with patient-centered interest groups to engage patients, optimize recruitment, and seamlessly return results. Finally, we developed a focused strategy for collective integration of our units. These synergies will allow us to become a national resource for optimal participant engagement, outreach, and communication approaches in genomic characterization studies, accelerating progress for researchers, patients, and their communities.




A Community-Engaged Approach to Enhancing Participation in Genomic Research in Rare and Understudied Cancer Populations.
Authors: Khan S. , Martin-Giacalone B. , Wallace K. , Wilson B. , Marx C. , Linnenbringer E. , Mozersky J. , Bachini M. , Chollet N. , Stalling D. , et al. .
Source: International Journal Of Environmental Research And Public Health, 2025-09-23 00:00:00.0; 22(10), .
EPub date: 2025-09-23 00:00:00.0.
PMID: 41154872
Related Citations

Optimizing a Patient-Centered Report of Somatic and Germline Genetic Test Results.
Authors: Anandarajah A. , Dart H. , Martin-Giacalone B. , Bacchini M. , Drake B.F. , Colditz G.A. , Fields R.C. , Ding L. , Linnenbringer E. .
Source: Jco Precision Oncology, 2025 Apr; 9, p. e2400927.
EPub date: 2025-04-18 00:00:00.0.
PMID: 40249881
Related Citations

Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer.
Authors: Earland N. , Semenkovich N.P. , Ramirez R.J. , Gerndt S.P. , Harris P.K. , Gu Z. , Hearn A.I. , Inkman M. , Szymanski J.J. , Whitfield D. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2024-04-01 00:00:00.0; 30(7), p. 1409-1421.
PMID: 37939112
Related Citations

High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival.
Authors: Storrs E.P. , Chati P. , Usmani A. , Sloan I. , Krasnick B.A. , Babbra R. , Harris P.K. , Sachs C.M. , Qaium F. , Chatterjee D. , et al. .
Source: Npj Precision Oncology, 2023-10-19 00:00:00.0; 7(1), p. 105.
EPub date: 2023-10-19 00:00:00.0.
PMID: 37857854
Related Citations

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer.
Authors: Semenkovich N.P. , Badiyan S.N. , Samson P.P. , Stowe H.B. , Wang Y.E. , Star R. , Devarakonda S. , Govindan R. , Waqar S.N. , Robinson C.G. , et al. .
Source: Npj Precision Oncology, 2023-10-02 00:00:00.0; 7(1), p. 100.
EPub date: 2023-10-02 00:00:00.0.
PMID: 37783809
Related Citations

Cell-Free DNA Liquid Biopsy: The Epitome of Personalized Precision Oncology.
Authors: Chaudhuri A.A. .
Source: Radiation Research, 2023-07-01 00:00:00.0; 200(1), p. 92-95.
PMID: 37084268
Related Citations

Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.
Authors: Earland N. , Chen K. , Semenkovich N.P. , Chauhan P.S. , Zevallos J.P. , Chaudhuri A.A. .
Source: Seminars In Radiation Oncology, 2023 Jul; 33(3), p. 262-278.
PMID: 37331781
Related Citations

Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA.
Authors: Semenkovich N.P. , Szymanski J.J. , Earland N. , Chauhan P.S. , Pellini B. , Chaudhuri A.A. .
Source: Journal For Immunotherapy Of Cancer, 2023 Jun; 11(6), .
PMID: 37349125
Related Citations

ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?
Authors: Pellini B. , Chaudhuri A.A. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2023-04-25 00:00:00.0; , p. OF1-OF3.
EPub date: 2023-04-25 00:00:00.0.
PMID: 37097069
Related Citations

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer.
Authors: Semenkovich N.P. , Samson P.P. , Badiyan S.N. , Vlacich G. , Stowe H.B. , Wang Y.E. , Star R. , Devarakonda S. , Govindan R. , Waqar S.N. , et al. .
Source: Research Square, 2023-03-22 00:00:00.0; , .
EPub date: 2023-03-22 00:00:00.0.
PMID: 36993328
Related Citations

Priorities to promote participant engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network.
Authors: Schuster A.L.R. , Crossnohere N.L. , Bachini M. , Blair C.K. , Carpten J.D. , Claus E.B. , Colditz G.A. , Ding L. , Drake B.F. , Fields R.C. , et al. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2023-02-15 00:00:00.0; , .
EPub date: 2023-02-15 00:00:00.0.
PMID: 36791345
Related Citations

Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
Authors: Pellini B. , Chaudhuri A.A. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2022-02-20 00:00:00.0; 40(6), p. 567-575.
EPub date: 2022-01-05 00:00:00.0.
PMID: 34985936
Related Citations